March 2021 Simoa® Publications:
Neurology: Alzheimer’s Disease, Stroke, and ALS
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Ashton NJ, et al.
Eur J Nucl Med Mol Imaging (2021)
Alzheimer’s Disease
Astrogliosis and Episodic Memory in Late Life: Higher GFAP is Related to Worse Memory and White Matter Microstructure in Healthy Aging and Alzheimer’s Disease
Bettcher BM, et al.
Neurobiology of Aging. 2021
Alzheimer’s Disease
Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes Might Allow Prehospital Thrombolysis
Bustamante A, et al.
Neurology. 2021
Stroke
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cicognola C, et al.
Alzheimers Res Ther. 2021;13:68
Alzheimer’s Disease
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
Clark C, et al.
Alzheimers Res Ther. 2021;13:65
Alzheimer’s Disease
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
Ding X, et al.
Transl Neurodegener. 2021;10:10
Alzheimer’s Disease
Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers
Pujol-Calderón F, et al.
Translational stroke research. 2021
Stroke
Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis
Yamada S, et al.
J Neurol Neurosurg Psychiatry. 2021 Mar 18;jnnp-2020-324615
ALS
March 2021 Simoa® Publications in Other Therapeutic Areas
